The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple ...
The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple ...
The study underscores the transformative potential of PacBio's long-read sequencing technology in diagnosing complex genetic diseases, paving the way for improved patient outcomes in genomic medicine.
“We are proud to partner with PacBio for their first human health-related commercial application,” said Paul Denslow, CEO of Intus Bio. “High accuracy, long-read sequencing is essential to ...
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud ...
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud ...